Search

The aim of the Public Health Emergency Preparedness Assessment, as mandated in Article 8 of Regulation (EU) 2022/2371 on serious cross-border threats to health, is to improve prevention, preparedness and response planning in European Union/European Economic Area (EU/EEA) countries through the implementation of recommendations following individual country assessments.

Highly pathogenic avian influenza A(H5N1) continues to circulate widely in wild birds and cause outbreaks in poultry and other animals across Europe. Despite extensive circulation, human infections remain rare and no human cases have been confirmed in the EU/EEA to date. 

On 26 August 2026, the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) submitted a request to ECDC for rapid scientific advice on the management of contacts following sporadic imported Andes orthohantavirus (ANDV) infections, including recommendations on contact classification, monitoring, laboratory testing and appropriate public health measures. 

This report presents the findings and recommendations of the first assessment conducted in Liechtenstein.

This after-action review focused on assessing key technical areas of outbreak response following a leptospirosis outbreak in Latvia.

In this scoping review, covering publications from January 2000 to June 2025, probable or certain transmission cases of arbovirus through substances of human origin SoHO were identified for WNV, DENV and Zika virus.

This survey report describes the testing requirements for Hepatitis C virus in different EU/EEA countries.

This survey report aims to describe the testing requirements for hepatis B virus in different EU/EEA countries.

Since 2022, an increasing number of European countries have reported cases of gonorrhoea caused by ceftriaxone-resistant Neisseria gonorrhoeae, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

An outbreak of Salmonella Stanley ST2045 is ongoing in the EU/EEA, with a total of 106 confirmed cases having been reported by 13 EU/EEA countries (77) and the United Kingdom (29) between November 2025 and June 2026.

Between 15 and 21 June 2026, the EUHTF conducted a fact-finding mission to the DRC and Uganda to assess airport exit screening procedures in the context of the ongoing outbreak of Ebola disease caused by the Bundibugyo virus.

Preliminary data from the main collection of the survey of carbapenem-resistant Enterobacterales 2025 (CRE25 survey) indicates a considerable change in the carbapenemase gene distribution in carbapenem-resistant or carbapenem-susceptible, increased exposure (carbapenem-R/I) Klebsiella pneumoniae species complex (SC).

Between January and May 2026, 109 confirmed cases of Salmonella Bovismorbificans ST377 were reported from 10 European Union/European Economic Area (EU/EEA) countries (Austria, Belgium, Czechia, Denmark, Finland, Germany, Ireland, Luxembourg, Spain and the Netherlands) and the United Kingdom.

This report presents the findings and recommendations of the first assessment conducted in Cyprus. This involved a desk review of relevant documents, followed by a five-day country visit that took place between 1and 5 December 2025.

This rapid systematic review aimed to identify and assess the strength and consistency of associations between clinical risk factors and severe RSV outcomes in adults.

Several clusters of genetically and epidemiologically linked cases predominantly affecting gay, bisexual and other men who have sex with men have been detected in four EU countries during the past six months. Cases have also been reported in Norway among individuals practicing martial arts, in 2025 and 2026.

This assessment presents an overview and critical appraisal of the available modelling evidence to inform the scale and potential spread of Bundibugyo virus (BDBV) in the context of the ongoing Ebola disease outbreak in the Democratic Republic of the Congo (DRC) and Uganda.

This report presents the findings and recommendations of the first assessment conducted in Lithuania. This involved a desk review of relevant documents, followed by a five-day country visit that took place between 15 September and 19 September 2025.

In this report, we present estimates of the probability of importation of Ebola disease caused by Bundibugyo virus (BDBV), into EU/EEA countries for the period 11–25 June 2026 under different assumptions of travel volumes from the areas where most cases were reported from.

The overall risk of Bundibugyo virus transmission through substances of human origin (SoHO) in the European Union/European Economic Area (EU/EEA) is currently assessed as very low.

This document aims to provide guidance for public health, healthcare providers and infection prevention and control (IPC) professionals in the EU/EEA regarding IPC measures should there be individuals meeting the criteria for ‘person under investigation’ (PUI).

The ongoing outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda reported in May 2026 has prompted ECDC to review its operational guidance relevant to air travel. In this context, updated guidance is needed to support preparedness and public health action if a case is identified during or after a flight.

The European Centre for Disease Prevention and Control (ECDC), the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) and the European Food Safety Authority (EFSA) conducted a country visit to Serbia from 24 to 28 February 2025.

On 15 May 2026, Africa CDC reported an outbreak of Ebola disease in Ituri Province, DRC. Laboratory analysis at Institut National de Recherche Biomedicale of DRC identified Bundibugyo virus (BDBV). BDBV disease is a rare disease but can cause outbreaks with high case fatality rates. Considering the available information, complicated context and the uncertainties on the epidemiological information WHO declared a Public Health Emergency of International Concern on 17 May 2026. Africa CDC declared a Public Health Emergency of Continental Security on 18 May 2026.

This document aims to provide advice on infection prevention and control (IPC) measures for healthcare facilities providing care to patients with suspected or confirmed ANDV disease.